Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Keeling

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Molecular Therapy. Nucleic Acids|May 15, 2020
Mutation-Directed Therapeutics for Neurofibromatosis Type IAndre Leier, David M Bedwell, Ann T Chen, et al.
AIDS Research and Human Retroviruses|May 15, 1998
Oral SIV, SHIV, and HIV type 1 infectionR M Ruprecht, T W Baba, V Liska, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 13, 2002
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgeneMing Du, Julie R Jones, Jessica Lanier, et al.
Molecular Therapy. Oncology|April 6, 2026
Identification of small molecules that enhance aminoglycoside-mediated suppression of <i>CFTR</i> and <i>NF1</i> nonsense mutationsJoshua Sammons, Jianguo Chen, Kari Thrasher, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2024
Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flowNovella M Keeling, Michael Wallisch, Jennifer Johnson, et al.
British Journal of Haematology|March 10, 2005
The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotypeDerrick J Bowen, Peter W Collins, Will Lester, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppressionBijoyita Roy, Westley J Friesen, Yuki Tomizawa, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2014
Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac functionKristin P Bibee, Ya-Jian Cheng, James K Ching, et al.
American Journal of Respiratory and Critical Care Medicine|April 23, 2016
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense MutationsVenkateshwar Mutyam, Ming Du, Xiaojiao Xue, et al.
International Journal of Molecular Sciences|March 11, 2023
Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome)Amna Siddiqui, Halil Dundar, Jyoti Sharma, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Molecular Therapy. Nucleic Acids|May 15, 2020
Mutation-Directed Therapeutics for Neurofibromatosis Type IAndre Leier, David M Bedwell, Ann T Chen, et al.
AIDS Research and Human Retroviruses|May 15, 1998
Oral SIV, SHIV, and HIV type 1 infectionR M Ruprecht, T W Baba, V Liska, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 13, 2002
Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgeneMing Du, Julie R Jones, Jessica Lanier, et al.
Molecular Therapy. Oncology|April 6, 2026
Identification of small molecules that enhance aminoglycoside-mediated suppression of <i>CFTR</i> and <i>NF1</i> nonsense mutationsJoshua Sammons, Jianguo Chen, Kari Thrasher, et al.
Journal of Thrombosis and Haemostasis : JTH|February 8, 2024
Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flowNovella M Keeling, Michael Wallisch, Jennifer Johnson, et al.
British Journal of Haematology|March 10, 2005
The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotypeDerrick J Bowen, Peter W Collins, Will Lester, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2016
Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppressionBijoyita Roy, Westley J Friesen, Yuki Tomizawa, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 7, 2014
Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac functionKristin P Bibee, Ya-Jian Cheng, James K Ching, et al.
American Journal of Respiratory and Critical Care Medicine|April 23, 2016
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense MutationsVenkateshwar Mutyam, Ming Du, Xiaojiao Xue, et al.
International Journal of Molecular Sciences|March 11, 2023
Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome)Amna Siddiqui, Halil Dundar, Jyoti Sharma, et al.
Pageof 13